Dataset Information

EXTERNAL VALIDATION OF THE DIABETES EARLY RE-ADMISSION RISK INDICATOR (DERRI^™).

ABSTRACT:

Objective

The Diabetes Early Re-admission Risk Indicator (DERRI^™) was previously developed and internally validated as a tool to predict the risk of all-cause re-admission within 30 days of discharge (30-day re-admission) of hospitalized patients with diabetes. In this study, the predictive performance of the DERRI^™ with and without additional predictors was assessed in an external sample.

Methods

We conducted a retrospective cohort study of adult patients with diabetes discharged from two academic medical centers between January 1, 2000 and December 31, 2014. We applied the previously developed DERRI^™, which includes admission laboratory results, sociodemographics, a diagnosis of certain comorbidities, and recent discharge information, and evaluated the effect of adding metabolic indicators on predictive performance using multivariable logistic regression. Total cholesterol and hemoglobin A1c (A1c) were selected based on clinical relevance and univariate association with 30-day re-admission.

Results

Among 105,974 discharges, 19,032 (18.0%) were followed by 30-day re-admission for any cause. The DERRI^™ had a C-statistic of 0.634 for 30-day re-admission. Total cholesterol was the lipid parameter most strongly associated with 30-day re-admission. The DERRI^™ predictors A1c and total cholesterol were significantly associated with 30-day re-admission; however, their addition to the DERRI^™ did not significantly change model performance (C-statistic, 0.643 [95% confidence interval, 0.638 to 0.647]; P = .92).

Conclusion

Performance of the DERRI^™ in this external cohort was modest but comparable to other re-admission prediction models. Addition of A1c and total cholesterol to the DERRI^™ did not significantly improve performance. Although the DERRI^™ may be useful to direct resources toward diabetes patients at higher risk, better prediction is needed.

Abbreviations

A1c = hemoglobin A1c; CI = confidence interval; DERRI^™ = Diabetes Early Re-admission Risk Indicator; GEE = generalized estimating equation; HDL-C = high-density-lipoprotein cholesterol; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; LDL-C = low-density-lipoprotein cholesterol.

SUBMITTER: Rubin DJ

PROVIDER: S-EPMC6413863 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

EXTERNAL VALIDATION OF THE DIABETES EARLY RE-ADMISSION RISK INDICATOR (DERRI<sup>™</sup>).

Rubin Daniel J DJ Recco Dominic D Turchin Alexander A Zhao Huaqing H Golden Sherita Hill SH

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20180406 6

<h4>Objective</h4>The Diabetes Early Re-admission Risk Indicator (DERRI<sup>™</sup>) was previously developed and internally validated as a tool to predict the risk of all-cause re-admission within 30 days of discharge (30-day re-admission) of hospitalized patients with diabetes. In this study, the predictive performance of the DERRI<sup>™</sup> with and without additional predictors was assessed in an external sample.<h4>Methods</h4>We conducted a retrospective cohort study of adult patients wi ...[more]

PMID: 29624095

Similar Datasets

Project description:Background and objectivesProgression of CKD toward ESRD is heterogeneous. The Kidney Failure Risk Equation (KFRE) was developed to identify CKD patients at high risk of ESRD. We aimed to externally validate KFRE and to test whether the addition of predefined Duplex ultrasound markers - renal resistive index (RRI) or difference of resistive indices in spleen and kidney (DI-RISK) - improved ESRD prediction.Design, setting, participants, & measurementsThe prospective Cardiovascular and Renal Outcome in CKD 2-4 Patients-The Fourth Homburg evaluation (CARE FOR HOMe) study recruits CKD stage G2-G4 patients referred to a tertiary referral center for nephrologic care. Four hundred three CARE FOR HOMe participants enrolled between 2008 and 2012 had available RRI measurements at study inclusion; they were subsequently followed for a mean of 4.4±1.6 years. This subcohort was used to validate KFRE and to assess the added value of the ultrasound markers (new models KFRE+RRI and KFRE+DI-RISK). Model performance was assessed by log-likelihood ratio test, c-statistic, integrated discrimination improvement metrics (for study participants without subsequent ESRD [IDI No ESRD] and for patients with ESRD [IDI ESRD]), and calibration plots. If either new model improved on KFRE, we determined to validate it in an independent cohort of 162 CKD patients.ResultsKFRE predicted ESRD in CARE FOR HOMe participants with a c-statistic of 0.91 (95% confidence interval, 0.83 to 0.99). Adding RRI improved the KFRE model (P<0.001), and the KFRE+RRI model was well calibrated; however, the c-statistic (0.91 [0.83-1.00]) was similar, and overall sensitivity (IDI No ESRD=0.05 [0.00-0.10]) or overall specificity (IDI ESRD=0.00 [0.00-0.01]) did not improve. Adding DI-RISK did not improve the KRFE model. In the external validation cohort, we confirmed that the KFRE+RRI model did not outperform KFRE.ConclusionsRoutine Duplex examinations among CKD patients did not improve risk prediction for progression to ESRD beyond a validated equation.

Project description:BackgroundIdentification of patients with novel coronavirus disease 2019 (COVID-19) requiring hospital admission or at high-risk of in-hospital mortality is essential to guide patient triage and to provide timely treatment for higher risk hospitalized patients.MethodsA retrospective multi-centre (8 hospital) cohort at Beaumont Health, Michigan, USA, reporting on COVID-19 patients diagnosed between 1 March and 1 April 2020 was used for score validation. The COVID-19 Risk of Complications Score was automatically computed by the EHR. Multivariate logistic regression models were built to predict hospital admission and in-hospital mortality using individual variables constituting the score. Validation was performed using both discrimination and calibration.ResultsCompared to Green scores, Yellow Scores (OR: 5.72) and Red Scores (OR: 19.1) had significantly higher odds of admission (both p < .0001). Similarly, Yellow Scores (OR: 4.73) and Red Scores (OR: 13.3) had significantly higher odds of in-hospital mortality than Green Scores (both p < .0001). The cross-validated C-Statistics for the external validation cohort showed good discrimination for both hospital admission (C = 0.79 (95% CI: 0.77-0.81)) and in-hospital mortality (C = 0.75 (95% CI: 0.71-0.78)).ConclusionsThe COVID-19 Risk of Complications Score predicts the need for hospital admission and in-hospital mortality patients with COVID-19. Key points: Can an electronic health record generated risk score predict the risk of hospital admission and in-hospital mortality in patients diagnosed with coronavirus disease 2019 (COVID-19)? In both validation cohorts of 2,025 and 1,290 COVID-19, the cross-validated C-Statistics showed good discrimination for both hospital admission (C = 0.79 (95% CI: 0.77-0.81)) and in-hospital mortality (C = 0.75 (95% CI: 0.71-0.78)), respectively. The COVID-19 Risk of Complications Score may help predict the need for hospital admission if a patient contracts SARS-CoV-2 infection and in-hospital mortality for a hospitalized patient with COVID-19.

Project description:ObjectiveTo identify existing prediction models for the risk of development of type 2 diabetes and to externally validate them in a large independent cohort.Data sourcesSystematic search of English, German, and Dutch literature in PubMed until February 2011 to identify prediction models for diabetes.DesignPerformance of the models was assessed in terms of discrimination (C statistic) and calibration (calibration plots and Hosmer-Lemeshow test).The validation study was a prospective cohort study, with a case cohort study in a random subcohort.SettingModels were applied to the Dutch cohort of the European Prospective Investigation into Cancer and Nutrition cohort study (EPIC-NL).Participants38,379 people aged 20-70 with no diabetes at baseline, 2506 of whom made up the random subcohort.Outcome measureIncident type 2 diabetes.ResultsThe review identified 16 studies containing 25 prediction models. We considered 12 models as basic because they were based on variables that can be assessed non-invasively and 13 models as extended because they additionally included conventional biomarkers such as glucose concentration. During a median follow-up of 10.2 years there were 924 cases in the full EPIC-NL cohort and 79 in the random subcohort. The C statistic for the basic models ranged from 0.74 (95% confidence interval 0.73 to 0.75) to 0.84 (0.82 to 0.85) for risk at 7.5 years. For prediction models including biomarkers the C statistic ranged from 0.81 (0.80 to 0.83) to 0.93 (0.92 to 0.94). Most prediction models overestimated the observed risk of diabetes, particularly at higher observed risks. After adjustment for differences in incidence of diabetes, calibration improved considerably.ConclusionsMost basic prediction models can identify people at high risk of developing diabetes in a time frame of five to 10 years. Models including biomarkers classified cases slightly better than basic ones. Most models overestimated the actual risk of diabetes. Existing prediction models therefore perform well to identify those at high risk, but cannot sufficiently quantify actual risk of future diabetes.

Dataset Information

EXTERNAL VALIDATION OF THE DIABETES EARLY RE-ADMISSION RISK INDICATOR (DERRI^™).

Objective

Methods

Results

Conclusion

Abbreviations

Publications

EXTERNAL VALIDATION OF THE DIABETES EARLY RE-ADMISSION RISK INDICATOR (DERRI<sup>™</sup>).

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

EXTERNAL VALIDATION OF THE DIABETES EARLY RE-ADMISSION RISK INDICATOR (DERRI™).

Objective

Methods

Results

Conclusion

Abbreviations

Publications

EXTERNAL VALIDATION OF THE DIABETES EARLY RE-ADMISSION RISK INDICATOR (DERRI<sup>™</sup>).

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

EXTERNAL VALIDATION OF THE DIABETES EARLY RE-ADMISSION RISK INDICATOR (DERRI^™).